Arkadiusz Kazula
Zastosowanie naturalnych kannabinoidów i endokannabinoidów w terapii
2009-03-25
The endocannabinoid system has been recently recognized as an important modulatory system. The important elements of this system are endocannabinoid receptors types CB1 and CB2, their endogenous ligands, enzymes involved in their synthesis and degradation. Currently there is a heightened interest in the analgesic potential of cannabinoid receptor agonists and synthetic agonists. Apart from analgesia, cannabinoids may find a place for example in the treatment of anorexia, spasticity, dyspnea, or glaucoma. It is therefore possible to speculate about a future clinical use of CB1 antagonists in prevention of cardiovascular disease and type 2 diabetes mellitus. Drugs acting as agonists of CB1 receptors (dronabinol, dexanabinol) are currently proposed for evaluation as drugs to treat neurodegenerative disorders (Alzheimer's and Parkinson's diseases), epilepsy, anxiety and stroke. Presently, concerns about the safety of cannabinoids prevent clinical use. It is anticipated that developments in pharmaceutical agents and formulations should overcame these clinical difficulties.
Zastosowanie naturalnych kannabinoidów i endokannabinoidów w terapii
522.52 kB |
21 grudnia 2017